Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Trading 11-26 12:17:16 EST

36.72

+0.84

+2.34%

High36.83	Low35.09	Vol14.61K
Open35.88	D1 Closing35.88	Amplitude4.85%
Mkt Cap1.01B	Tradable Cap459.61M	Total Shares27.50M
T/O527.95K	T/O Rate0.12%	Tradable Shares12.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":36.72,"timestamp":1732641421391,"preClose":35.88,"halted":0,"volume":14614,"delay":0,"floatShares":12516629,"shares":27500892,"eps":-2.688476,"marketStatus":"Trading","change":0.84,"latestTime":"11-26 12:17:16 EST","open":35.88,"high":36.83,"low":35.09,"amount":527951.50188,"amplitude":0.048495,"askPrice":36.89,"askSize":332,"bidPrice":36.58,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.688476,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732654800000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":35.88,"preHourTrading":{"tag":"盘前","latestPrice":35.88,"preClose":35.88,"latestTime":"09:29 EST","volume":17,"amount":638.50997,"timestamp":1732631399915},"postHourTrading":{"tag":"盘后","latestPrice":35.8784,"preClose":35.88,"latestTime":"19:18 EST","volume":26828,"amount":962569.4155,"timestamp":1732580295576},"volumeRatio":0.26944},"requestUrl":"/m/hq/s/LENZ/wiki","defaultTab":"wiki","newsList":[{"id":"2486883977","title":"Poseida Therapeutics Cut to Market Perform From Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2486883977","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486883977?lang=en_us&edition=fundamental","pubTime":"2024-11-27 00:24","pubTimestamp":1732638240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2024 11:24 ET (16:24 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","PSTX"],"gpt_icon":0},{"id":"2486881318","title":"Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2486881318","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486881318?lang=en_us&edition=fundamental","pubTime":"2024-11-27 00:00","pubTimestamp":1732636800,"startTime":"0","endTime":"0","summary":"HOUSTON, Nov.  26, 2024  (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987657/0/en/Marker-Therapeutics-to-Present-at-the-Citizens-JMP-Hematology-and-Oncology-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMF","BK4139","LENZ","BK4211","BK4127","JMP"],"gpt_icon":0},{"id":"2486007383","title":"Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2486007383","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486007383?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:15","pubTimestamp":1732634100,"startTime":"0","endTime":"0","summary":"NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on December 3, 2024, at 11:00 a.m. ET.The exclusive event, hosted by RedChip Companies, will feature Enlivex Therapeutics Chief Executive Officer Oren Hershkovitz who will share insight into the Company's lead product, Allocetra, insight into the clinical status, and 2025 planned catalysts.Allocetra is an off-the-shelf, cell therapy technology that reprograms non-homeostatic macrophages to their optimal functioning state, addressing critical unmet needs in conditions like osteoarthritis, sepsis, and psoriatic arthritis. With Phase I/II clinical trials showing promising results and targeting multi-billion-dollar markets, Allocetra has the potential to redefine treatment paradigms for inflammatory and autoimmune diseases.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/StCuUlZ6kiI77aswZvUxig--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/8bb34287933874f442490c8cb760fd05","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/StCuUlZ6kiI77aswZvUxig--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/8bb34287933874f442490c8cb760fd05"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/join-enlivex-therapeutics-exclusive-live-151500357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENLV","BK4139","LENZ"],"gpt_icon":0},{"id":"2486002310","title":"Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2486002310","media":"Dow Jones","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486002310?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:12","pubTimestamp":1732633920,"startTime":"0","endTime":"0","summary":"10:12 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth. The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. Roche is buying Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 Monday. Dow Jones & Co. owns Factiva. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","BK4139","BK4007","RHHBY","LENZ","PSTX"],"gpt_icon":0},{"id":"2486199004","title":"Poseida Therapeutics Up Nearly 225%, On Pace For Record High Close -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2486199004","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486199004?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:03","pubTimestamp":1732633380,"startTime":"0","endTime":"0","summary":"Poseida Therapeutics, Inc.  is currently at $9.29, up $6.43 or 224.78%. --Would be highest close since Aug. 30, 2021, when it closed at $10.71. --Currently up three consecutive days; up 242.76% over this period. --Up 291.93% month-to-date; on pace for best month on record . --Up 176.45% year-to-date; on pace for best year on record . --Down 42.84% from its all-time closing high of $16.25 on July 20, 2020. --Up 250.52% from 52 weeks ago , when it closed at $2.65. --Up 364.44% from its 52-week closing low of $2.00 on April 18, 2024. --Traded as high as $9.32; highest intraday level since Aug. 31, 2021, when it hit $10.89","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTX","LENZ"],"gpt_icon":0},{"id":"2486006741","title":"Actuate Therapeutics to Join Russell 2000 Index; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2486006741","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486006741?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:25","pubTimestamp":1732631119,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics  said Tuesday it will join the Russell 2000 Index effective after the opening of markets on Dec. 23.The company said it will be added to the index as part of the planned Q4 initial public offering additions.Shares of Actuate Therapeutics rose 9.3% in premarket activity Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","ACTU"],"gpt_icon":0},{"id":"2486006425","title":"Poseida Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2486006425","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486006425?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:24","pubTimestamp":1732631040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2024 09:24 ET (14:24 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTX","LENZ"],"gpt_icon":0},{"id":"2486005700","title":"Tenaya Therapeutics Price Target Announced at $18.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2486005700","media":"Dow Jones","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486005700?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:10","pubTimestamp":1732630200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TNYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2024 09:10 ET (14:10 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","LENZ"],"gpt_icon":0},{"id":"2486700575","title":"Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details","url":"https://stock-news.laohu8.com/highlight/detail?id=2486700575","media":"Benzinga","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486700575?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:07","pubTimestamp":1732630028,"startTime":"0","endTime":"0","summary":"On Tuesday, Roche Holdings AG  agreed to acquire Poseida Therapeutics, Inc.  for an equity value of approximately$1.5 billionon a fully diluted basis.The deal consideration includes $9.00per share in cash plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of$4.00per share in cash upon achievement of specific milestones.Also Read: Roche’s Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings’ $16.5B Catalent Acquisition. The proposed acquisition will establish a new core capability forRoche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies.It will include CAR-T programs for solid tumors and autoimmune diseases, Poseida’s genetic engineering platform, and related preclinical medicines.The acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therap","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/g4jTRZDi3y.XJAenQDZSdA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/658b5c3c7cbb8a183e1572a7bc98d884","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/g4jTRZDi3y.XJAenQDZSdA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/658b5c3c7cbb8a183e1572a7bc98d884"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roches-proposed-acquisition-poseida-therapeutics-140708524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PSTX","LENZ"],"gpt_icon":0},{"id":"2486300539","title":"Poseida Therapeutics downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2486300539","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486300539?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:00","pubTimestamp":1732629611,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Arthur He downgraded Poseida Therapeutics (PSTX) to Neutral from Buy with a price target of $9, down from $20, after Roche ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/poseida-therapeutics-downgraded-to-neutral-from-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/poseida-therapeutics-downgraded-to-neutral-from-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSTX","LENZ"],"gpt_icon":0},{"id":"2486005432","title":"Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality","url":"https://stock-news.laohu8.com/highlight/detail?id=2486005432","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486005432?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:45","pubTimestamp":1732628700,"startTime":"0","endTime":"0","summary":"The Phase 1b clinical trial design presented at SNO2024 combines LP-184  with spironolactone to potentially enhance therapeutic response in recurrent glioblastoma  patients.Preclinical data, including in previously published research by Lantern Pharma, demonstrates up to 6-fold increase in GBM cell sensitivity when LP-184 is combined with spironolactone.The clinical development for LP-184 in CNS cancers is planned to be advanced as STAR-001 by Starlight Therapeutics in later stage human clinical trials.The poster presentation highlighted LP-184's unique mechanism of action, brain penetrance properties, and potential enhanced therapeutic effect when combined with spironolactone in glioblastoma multiforme . LP-184 is currently under investigation in a Phase 1a dose-escalation safety study  in adult patients with advanced solid tumors including GBM.Preclinical studies show spironolactone increases GBM cell sensitivity to LP-184 up to 6-fold through ERCC3 degradation – which induces NERD  ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jKX7AND1_9UFj7U4dqCxUg--~B/aD02MTU7dz0yMDM0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/71db1cc7d46eb00b91e123db19fc71f5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jKX7AND1_9UFj7U4dqCxUg--~B/aD02MTU7dz0yMDM0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/71db1cc7d46eb00b91e123db19fc71f5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lantern-pharma-starlight-therapeutics-present-134500541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","BK4139","BK4585","LU1721428933.USD","LU1093756168.USD","LENZ","WRD","ADC","BK4121","MTD","LTRN","BK4588","LU0347712357.USD","BK4231","BK4548","LU1093756325.SGD","BK4567","LU2413666426.HKD","BK4080","LU2413666699.HKD"],"gpt_icon":0},{"id":"2486008724","title":"Keros Therapeutics Showcases Innovations at Major Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2486008724","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486008724?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:28","pubTimestamp":1732627705,"startTime":"0","endTime":"0","summary":"An announcement from Keros Therapeutics ( ($KROS) ) is now available. Keros Therapeutics, a clinical-stage biopharmaceutical company, is set to mak...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/keros-therapeutics-showcases-innovations-at-major-conferences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/keros-therapeutics-showcases-innovations-at-major-conferences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","KROS"],"gpt_icon":0},{"id":"2486070141","title":"Actuate Therapeutics added to Russell 2000 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2486070141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486070141?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:16","pubTimestamp":1732626972,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced that the Company will be added to the Russell 2000 Index as part of the planned fourth quarter IPO additions ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-added-to-russell-2000-index?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-added-to-russell-2000-index?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","LENZ","BK4139"],"gpt_icon":0},{"id":"2486507714","title":"Aligos Therapeutics to Present at Investor Conferences in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2486507714","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486507714?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:00","pubTimestamp":1732626000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov.  26, 2024  (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987464/0/en/Aligos-Therapeutics-to-Present-at-Investor-Conferences-in-December.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","WRD","BK4139","LENZ","ALGS"],"gpt_icon":0},{"id":"2486128077","title":"Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2486128077","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486128077?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:00","pubTimestamp":1732626000,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., Nov. 26, 2024  -- Keros Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta  family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:. Date and Time: Tuesday, December 3, 2024 at 10:30 a.m. Eastern time","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ljBZsb8HTr.P.ouI20ICHg--~B/aD02MzU7dz0xNzg5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32d571da8b4f8883a54fc4e04672f17a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ljBZsb8HTr.P.ouI20ICHg--~B/aD02MzU7dz0xNzg5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32d571da8b4f8883a54fc4e04672f17a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keros-therapeutics-announces-participation-upcoming-130000748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","BK4139","LENZ","KROS","BK4137"],"gpt_icon":0},{"id":"2486077768","title":"Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486077768","media":"Business Wire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486077768?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:00","pubTimestamp":1732626000,"startTime":"0","endTime":"0","summary":"LONDON, November 26, 2024----Silence Therapeutics plc, Nasdaq: SLN , a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 10:00 a.m. ET.The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.Inquiries:Silence Therapeutics plc Gem Hopkins, VP, Head of IR and Corporate Communicationsir@silence-therapeutics.com Tel: +1  637-3208","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/W8eOCZRQEwV0jAFvgQOLew--~B/aD02NTI7dz0xNzU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1f32c9b36919d4fe23dfae2d1b824536","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/W8eOCZRQEwV0jAFvgQOLew--~B/aD02NTI7dz0xNzU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1f32c9b36919d4fe23dfae2d1b824536"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silence-therapeutics-participate-fireside-chat-130000606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","SLN","BK4137","HCSG"],"gpt_icon":0},{"id":"2486077126","title":"Actuate Therapeutics to be Added to Russell 2000® Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2486077126","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486077126?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:00","pubTimestamp":1732626000,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, Nov.  26, 2024  (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on develop","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987459/0/en/Actuate-Therapeutics-to-be-Added-to-Russell-2000-Index.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139","WRD","LENZ"],"gpt_icon":0},{"id":"2486007757","title":"Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2486007757","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486007757?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:40","pubTimestamp":1732624813,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics  provided an update on a biomarker analysis from the Phase 2 ‘SHINE’ study in mild-to-moderate Alzheimer’s disease. This new analysis focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau2172. Several blood-based measures of Alzheimer’s disease biology were identified that were normalized in CT1812-treated participants compared to the placebo-treated participants. These biomarker changes occurred in concert with a 95% slowing of cognitive decline as measured by ADAS-Cog11 in the same patients. These data provide further evidence that CT1812 may be preserving cognitive function and slowing disease progression by protecting key neurological system. In this new analysis, the Company reported changes in plasma biomarkers that may reflect Alzheimer’s disease pathology. The results demonstrated that individuals who entered the study with plasma p-tau217 below the median experienced a normalization of several key indicat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tXfTVJ1OixCCbB5e.FsdJg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/38a68defd725ddd544390055e985cfb8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tXfTVJ1OixCCbB5e.FsdJg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/38a68defd725ddd544390055e985cfb8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cognition-therapeutics-provided-phase-2-124013009.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cognition-therapeutics-provided-phase-2-124013009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","BK4007","CGTX"],"gpt_icon":0},{"id":"2486074492","title":"Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2486074492","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486074492?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:30","pubTimestamp":1732624200,"startTime":"0","endTime":"0","summary":"–Topline results in second dementia indication expected to be reported in December 2024 – PURCHASE, N.Y., Nov.  26, 2024  (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987398/0/en/Cognition-Therapeutics-Announces-all-Participants-have-Completed-their-Final-Visits-in-the-Phase-2-SHIMMER-Study-of-CT1812-in-Dementia-with-Lewy-Bodies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205194284.USD","LU0205193047.USD","LU0240877869.USD","LU0240878834.USD","LU0345774391.USD","BK4007","BK4097","LU0345774631.USD","CAF","DLB","LENZ","WRD","BK4139","CGTX","LU0348723411.USD"],"gpt_icon":0},{"id":"2486071041","title":"Transcode Therapeutics announces 1-for-33 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2486071041","media":"TipRanks","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486071041?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:05","pubTimestamp":1732622720,"startTime":"0","endTime":"0","summary":"Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Transcode Therapeutics Reports Increased Losses Amid Funding Challenges. Transcode Therapeutics announces Nasdaq extension to regain compliance. Transcode announces SRC approval of second cohort in Phase 1 TTX-MC138 trial","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/transcode-therapeutics-announces-1-33-120520053.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/transcode-therapeutics-announces-1-33-120520053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNAZ","BK4539","BK4139","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.graphitebio.com","stockEarnings":[{"period":"1week","weight":0.0899},{"period":"1month","weight":0.3279},{"period":"3month","weight":0.6309},{"period":"6month","weight":1.3163},{"period":"1year","weight":1.1812},{"period":"ytd","weight":0.9564}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.187611},{"month":2,"riseRate":0.666667,"avgChangeRate":0.15153},{"month":3,"riseRate":0,"avgChangeRate":-0.19103},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.06634},{"month":5,"riseRate":0,"avgChangeRate":-0.187229},{"month":6,"riseRate":0.666667,"avgChangeRate":0.07217},{"month":7,"riseRate":0.5,"avgChangeRate":0.062427},{"month":8,"riseRate":0.25,"avgChangeRate":-0.053734},{"month":9,"riseRate":0.5,"avgChangeRate":-0.017856},{"month":10,"riseRate":0.75,"avgChangeRate":0.006056},{"month":11,"riseRate":0.5,"avgChangeRate":-0.010947},{"month":12,"riseRate":0.666667,"avgChangeRate":0.157581}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}